Aimei Health (NASDAQ: AFJK) terminates United Hydrogen business combination deal
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Aimei Health Technology Co., Ltd. has terminated its planned business combination with United Hydrogen Group Inc. and related Cayman entities. The company sent a termination notice on July 7, 2026 under Section 9.1(b) of the Business Combination Agreement after the deal failed to close by the applicable outside date.
As a result, the Business Combination Agreement, originally signed on June 19, 2024 and amended on June 6, 2025, is no longer in effect and the proposed transaction will not be consummated. Aimei’s CEO stated the company remains confident in finding a compelling future transaction.
Positive
- None.
Negative
- Termination of announced merger: The Business Combination Agreement with United Hydrogen and related entities has been terminated after the deal was not completed by the outside date, leaving Aimei without its previously identified business combination target.
Insights
Aimei’s planned merger with United Hydrogen has lapsed after missing its outside date.
Aimei Health Technology, a blank-check company, has ended its Business Combination Agreement with United Hydrogen Group Inc. after the transaction was not completed by the agreed outside date, triggering a contractual termination right under Section 9.1(b).
For a SPAC, losing an announced target is significant because it removes the identified path to a business combination and returns the vehicle to deal-search mode. The company’s statement emphasizes intent to pursue another “compelling transaction,” but no alternatives are disclosed in this content.
Investors may focus on subsequent disclosures for updates on any new proposed business combination and on the remaining lifecycle of the SPAC structure, including any future shareholder votes or deadlines described in later filings.
8-K Event Classification
3 items: 1.02, 7.01, 9.01
3 items
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Agreement signing date: June 19, 2024
Agreement amendment date: June 6, 2025
Termination notice date: July 7, 2026
3 metrics
Agreement signing date
June 19, 2024
Business Combination Agreement execution date
Agreement amendment date
June 6, 2025
Amendment to Business Combination Agreement
Termination notice date
July 7, 2026
Date Aimei terminated Business Combination Agreement
Key Terms
Business Combination Agreement, outside date, Regulation FD Disclosure, emerging growth company
4 terms
Business Combination Agreement financial
"entered into a definitive Business Combination Agreement (as amended on June 6, 2025"
A business combination agreement is a detailed contract that lays out the terms for two companies to join together—covering price, how ownership will be split, the steps needed to close the deal, and what each side promises to do or avoid before closing. For investors it matters because the agreement determines potential changes in value, control, timing, and risk exposure—think of it like the playbook for a merger that shows who wins, who pays, and what could still derail the plan.
outside date financial
"The termination was triggered by the occurrence of the applicable outside date"
An outside date is the final contractual deadline by which a planned deal—such as a merger, acquisition, or financing—must be completed; if the transaction hasn’t closed by that date, parties typically gain the right to walk away or trigger agreed remedies. It matters to investors because it sets a clear timetable for when uncertainty should end, and approaching or missing the outside date can raise the chance of deal failure, renegotiation, or changes to valuation.
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure On July 7, 2026, the Company issued a press release"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Aimei Health Technology (AFJK) announce in this 8-K filing?
Aimei Health Technology announced it has terminated its Business Combination Agreement with United Hydrogen Group Inc. and related entities. The company delivered a termination notice on July 7, 2026, so the proposed business combination will not be consummated under the existing agreement.
Why was the Aimei Health–United Hydrogen business combination terminated?
The termination was triggered by the agreement’s outside date being reached without closing the transaction. Under Section 9.1(b) of the Business Combination Agreement, Aimei had the right to terminate once the proposed business combination was not completed by that contractual deadline.
When was the Business Combination Agreement between Aimei Health and United Hydrogen originally signed and amended?
The Business Combination Agreement between Aimei Health and United Hydrogen was originally signed on June 19, 2024. It was subsequently amended on June 6, 2025, before ultimately being terminated by Aimei’s notice delivered on July 7, 2026, effective immediately.
What does Aimei Health’s CEO say about future plans after ending the United Hydrogen deal?
Aimei’s CEO, Xie Junheng, stated the company remains confident in its ability to identify and execute a compelling transaction in the future. He also thanked the United Hydrogen team for their efforts and professionalism throughout the process, indicating an intention to pursue another suitable combination.
Did Aimei Health issue a press release about terminating the United Hydrogen agreement?
Yes. Aimei Health issued a press release on July 8, 2026, announcing the termination of the Business Combination Agreement. The press release was furnished as Exhibit 99.1 to the report and is incorporated by reference under the Regulation FD Disclosure section.
Which securities of Aimei Health Technology are listed on Nasdaq?
Aimei Health’s Nasdaq-listed securities include Ordinary Shares, par value $0.0001 per share, under symbol AFJK; Rights, exchangeable into one-fifth of one Ordinary Share, under AFJKR; and Units, each consisting of one Ordinary Share and one Right, under AFJKU.